Ciclindole
| Clinical data | |
|---|---|
| Other names | WIN-27,147-2; WIN-27147-2; WIN27147-2 |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H18N2 |
| Molar mass | 214.312 g·mol−1 |
| 3D model (JSmol) | |
| |
Ciclindole (INN; developmental code name WIN-27,147-2), also known as cyclindole (USAN), is an antipsychotic of the tetrahydrocarbazolamine family with a tricyclic cyclized tryptamine structure that was never marketed.
It displaces spiperone binding in vitro and elevates dopamine levels in the striatum, indicating that it acts as a dopamine D2 receptor antagonist. It also shows apparent affinity for the α1-adrenergic receptor, the serotonin S1 receptor, and the serotonin S2 receptor. However, its affinities for all of the preceding targets are weak, in the low micromolar range.
The related drug flucindole is about 5 to 10 times more potent than ciclindole both in vitro and in vivo.